Accelerated FDA approval of the first-in-class CELMoD agent iberdomide (Zenbexus) offers a new oral option for adults with relapsed or refractory multiple myeloma.
MHT use linked to significantly lower odds of clinical dementia diagnoses and symptoms of memory/functional decline ...
Administration of dexamethasone eye drops reduces the proportion of preterm infants with prethreshold retinopathy of prematurity (ROP) progressing to type 1 ROP ...
HealthDay News — A new executive order calls for American children to be routinely immunized against 11 diseases instead of the 17 now recommended by federal health officials. President Donald Trump ...
Casgevy (exagamglogene autotemcel) Autologous genome-edited hematopoietic stem cell-based gene therapy Treatment of patients aged 2 years and older with sickle cell disease with recurrent ...
Prespecified primary analyses showed significant improvement over placebo in patients aged 71 and older and those with a baseline 6MWD below 333 meters.
A Prescription Drug User Fee Act target date of February 12, 2027 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...
Thirteen conditional recommendations developed, including in relation to guiding therapy during exacerbations.
FDA acceptance of the new drug application for lonafarnib marks a key milestone toward an oral treatment option for chronic hepatitis D.
The mRNA-based influenza vaccine is expected to be available in the coming weeks. The Food and Drug Administration (FDA) has approved mFlusiva ®, the first mRNA-based influenza vaccine, for adults ...
The 4C meningococcal B (MenB) vaccine confers modest protection against gonorrhea among adolescents, according to a study published online August 4 in Open Foru ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results